0001209191-21-021943.txt : 20210318
0001209191-21-021943.hdr.sgml : 20210318
20210318204439
ACCESSION NUMBER: 0001209191-21-021943
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210316
FILED AS OF DATE: 20210318
DATE AS OF CHANGE: 20210318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ho Robert
CENTRAL INDEX KEY: 0001806254
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36327
FILM NUMBER: 21756192
MAIL ADDRESS:
STREET 1: 360-1616 EASTLAKE AVENUE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-732-2133
MAIL ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC
DATE OF NAME CHANGE: 20140128
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC
DATE OF NAME CHANGE: 20070626
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-16
0
0001404644
Neoleukin Therapeutics, Inc.
NLTX
0001806254
Ho Robert
C/O NEOLEUKIN THERAPEUTICS, INC.
188 EAST BLAINE STREET, #450
SEATTLE
WA
98102
0
1
0
0
Chief Financial Officer
Common Stock
2021-03-16
4
M
0
25000
0.00
A
28000
D
Common Stock
2021-03-17
4
S
0
6497
11.0137
D
21503
D
Restricted Stock Units
0.00
2021-03-16
4
M
0
25000
0.00
A
Common Stock
25000
50000
D
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.
/s/ Robert Ho
2021-03-18